drugset / Trial / NCT01437982
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
RandomizedSingle-groupTriple-blindTreatment
Summary
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
Timeline
- Start
- 2010-08-05
- Primary completion
- 2015-10-19
- Completion
- 2015-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Loteprednol Etabonate | Other / unclassified | 0.5 % | Other |
| Subject | Prednisolone | Other / unclassified | 1 % | Other |